Somerset Indus Capital Partners has invested around Rs 75 crore at a pre-money valuation of Rs 250 crore in Natural Capsules’ unlisted subsidiary -- Natural BioGenex (NBPL). As a result of this transaction, Somerset will hold a stake of between 23% and 28% in NBPL, underscoring their confidence in the company's growth potential and long-term success.
NBPL is constructing a state-of-the-art Greenfield facility in Tumkur, near Bengaluru. This state-of-the-art plant will manufacture active pharmaceutical ingredients (APIs), including Betamethasone, Dexamethasone, and Prednisolone, along with their intermediates and derivatives. The facility will not only enhance India's self-reliance in the API manufacturing sector but also contribute to the reduction of import dependency, particularly from China.
Natural Capsules is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1788.90 |
Dr. Reddys Lab | 1185.95 |
Cipla | 1533.55 |
Lupin | 2088.85 |
Zydus Lifesciences | 868.20 |
View more.. |